These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21083258)

  • 1. Microdosing: current and the future.
    Lappin G
    Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel strategies for microdose studies using non-radiolabeled compounds.
    Maeda K; Sugiyama Y
    Adv Drug Deliv Rev; 2011 Jun; 63(7):532-8. PubMed ID: 21345359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdosing: the new pharmacokinetic paradigm?
    Zanni GR; Wick JY
    Consult Pharm; 2006 Oct; 21(10):756-76. PubMed ID: 17243857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical, legal, and social implications (ELSI) of microdose clinical trials.
    Kurihara C
    Adv Drug Deliv Rev; 2011 Jun; 63(7):503-10. PubMed ID: 21251940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
    Sandhu P; Vogel JS; Rose MJ; Ubick EA; Brunner JE; Wallace MA; Adelsberger JK; Baker MP; Henderson PT; Pearson PG; Baillie TA
    Drug Metab Dispos; 2004 Nov; 32(11):1254-9. PubMed ID: 15286054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
    Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
    Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microdosing for early biokinetic studies in humans.
    Stenström K; Sydoff M; Mattsson S
    Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microdosing in early lead discovery.
    Jekunen AP; Pauwels EK; Kairemo KJ
    Bioanalysis; 2010 Mar; 2(3):421-8. PubMed ID: 21083252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
    Lappin G; Garner RC
    Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of microdosing over the past 5 years.
    Lappin G; Garner RC
    Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1499-506. PubMed ID: 19040326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
    Ings RM
    Bioanalysis; 2009 Oct; 1(7):1293-305. PubMed ID: 21083052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of microdosing clinical study -- why necessary and how useful?
    Sugiyama Y; Yamashita S
    Adv Drug Deliv Rev; 2011 Jun; 63(7):494-502. PubMed ID: 20950660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New ultrasensitive detection technologies and techniques for use in microdosing studies.
    Lappin G; Wagner CC; Langer O; van de Merbel N
    Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development.
    Oosterhuis B
    Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246
    [No Abstract]   [Full Text] [Related]  

  • 18. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
    Bae SK; Shon JH
    Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microdosing and drug development: past, present and future.
    Lappin G; Noveck R; Burt T
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):817-34. PubMed ID: 23550938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
    Yamazaki A; Kumagai Y; Yamane N; Tozuka Z; Sugiyama Y; Fujita T; Yokota S; Maeda M
    J Clin Pharm Ther; 2010 Apr; 35(2):169-75. PubMed ID: 20456735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.